Equities Analysts Offer Predictions for IRWD Q3 Earnings

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Free Report) - Research analysts at Zacks Research increased their Q3 2025 earnings per share estimates for shares of Ironwood Pharmaceuticals in a report released on Thursday, May 1st. Zacks Research analyst R. Department now anticipates that the biotechnology company will post earnings per share of $0.08 for the quarter, up from their prior forecast of $0.06. The consensus estimate for Ironwood Pharmaceuticals' current full-year earnings is $0.10 per share.

Other equities research analysts have also issued reports about the company. Craig Hallum lowered Ironwood Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, April 16th. JMP Securities lowered their price objective on Ironwood Pharmaceuticals from $23.00 to $14.00 and set a "market outperform" rating on the stock in a research report on Thursday, January 30th. Jefferies Financial Group reiterated a "hold" rating and set a $0.70 price objective (down from $8.00) on shares of Ironwood Pharmaceuticals in a research note on Tuesday, April 15th. Leerink Partners decreased their target price on shares of Ironwood Pharmaceuticals from $3.00 to $1.00 and set a "market perform" rating on the stock in a research note on Monday, April 14th. Finally, StockNews.com cut shares of Ironwood Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Tuesday, April 15th. Eight investment analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. According to MarketBeat, the company has an average rating of "Hold" and an average target price of $4.78.

Ironwood Pharmaceuticals Trading Down 0.1 %

NASDAQ IRWD traded down $0.00 during trading hours on Friday, hitting $0.93. 1,388,766 shares of the company's stock traded hands, compared to its average volume of 2,551,466. Ironwood Pharmaceuticals has a 52 week low of $0.59 and a 52 week high of $8.23. The firm has a market capitalization of $149.98 million, a P/E ratio of -30.90 and a beta of 0.37. The business's fifty day moving average price is $1.21 and its two-hundred day moving average price is $2.74.

Ironwood Pharmaceuticals (NASDAQ:IRWD - Get Free Report) last announced its earnings results on Thursday, February 27th. The biotechnology company reported $0.02 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.10 by ($0.08). Ironwood Pharmaceuticals had a negative return on equity of 0.96% and a negative net margin of 0.65%. The firm had revenue of $90.55 million during the quarter, compared to analysts' expectations of $93.85 million.

Insider Buying and Selling at Ironwood Pharmaceuticals

In other news, CEO Thomas A. Mccourt sold 139,064 shares of the stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of $1.76, for a total transaction of $244,752.64. Following the completion of the transaction, the chief executive officer now directly owns 1,160,634 shares in the company, valued at approximately $2,042,715.84. This represents a 10.70 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CMO Michael Shetzline sold 41,269 shares of the company's stock in a transaction on Monday, February 10th. The shares were sold at an average price of $1.76, for a total transaction of $72,633.44. Following the sale, the chief marketing officer now directly owns 554,007 shares in the company, valued at approximately $975,052.32. The trade was a 6.93 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 192,381 shares of company stock valued at $338,591 in the last three months. 12.90% of the stock is currently owned by corporate insiders.

Institutional Trading of Ironwood Pharmaceuticals

Several hedge funds have recently made changes to their positions in the business. Virtu Financial LLC purchased a new stake in Ironwood Pharmaceuticals during the third quarter valued at approximately $78,000. Hennion & Walsh Asset Management Inc. increased its position in shares of Ironwood Pharmaceuticals by 9.9% during the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 187,773 shares of the biotechnology company's stock valued at $832,000 after purchasing an additional 16,962 shares during the last quarter. SG Americas Securities LLC purchased a new stake in Ironwood Pharmaceuticals during the 4th quarter valued at $53,000. Pacer Advisors Inc. lifted its position in Ironwood Pharmaceuticals by 4.0% in the fourth quarter. Pacer Advisors Inc. now owns 11,730,771 shares of the biotechnology company's stock worth $51,967,000 after buying an additional 450,949 shares during the last quarter. Finally, EMC Capital Management boosted its stake in Ironwood Pharmaceuticals by 693.0% during the fourth quarter. EMC Capital Management now owns 23,893 shares of the biotechnology company's stock worth $106,000 after buying an additional 20,880 shares during the period.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.